GLASGOW, SCOTLAND , Feb. 01, 2018 -- HCi Viocare has been advised of a significant increase in the share price and trading volume of the Company's shares beginning Wednesday January 31, 2018.
The Company has been advised by OTC Markets Group that the Company is the subject of a promotional campaign by newsletter writers. The material being distributed contains promotional language pertaining to the Company's business, activities and future share price. The promotional campaign coincides with, and appears to have effected, a significant increase in the share price and trading volume of the Company's shares beginning Wednesday January 31, 2018.
The Company and its officers and directors did not authorize or participate in the promotional campaign in any way and do not endorse it. The Company and its officers and directors only became aware of the promotional campaign when advised by OTC Markets Group.
A disclaimer by three of the letter writers indicates that World Wide Media Group LLC engaged, and compensated, the letter writer for the promotional campaign. The Company and its officers and directors:
· Do not know who beneficially owns controls or represents World Wide Media Group LLC.
· Has never had contact with nor knows who BullFreak, tradeRally, AwesomeStockTips or ShiznitStocks are,
· Do not know if any of the above owns shares of the Company,
· Did not participate in, or benefit from, trading in the shares of the Company during the promotional campaign.
· The promotional material contains information available to the public from the SEC site or the OTC Markets site
· The information pertaining to the “Tharawat” joint venture is not accurate as and has been terminated as detailed in our 8K filing of Wednesday January 31, 2018
· Some of the statements in the promotional material being the opinions of the writers are overly promotional
· The company does not have any IR Services, public relations services, paid promotion, marketing or other related services at this time.
The company does not have any convertible instruments convertible at a discount to the market price in place at this time.
The Company and its officers and directors are unaware of any business reason for this market activity and price increase. All material developments concerning the Company of which its officers and directors are aware have been disclosed in the Company's filings with OTC Markets. The Company encourages anyone interested in the Company to review its filings with OTC Markets (US).
Contact: Poppy Kaponikolou 00306981144421 [email protected]


Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Anta Sports Expands Global Footprint With Strategic Puma Stake
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



